Skip to main content
Liaoning Cheng Da Co.,Ltd. logo

Liaoning Cheng Da Co.,Ltd. — Investor Relations & Filings

Ticker · 600739 ISIN · CNE000000LY3 LEI · 300300ZCCWKNUJRL8D79 Shanghai Stock Exchange Financial and insurance activities
Open in API
Filings indexed 2,288 across all filing types
Latest filing 2022-02-11 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600739

About Liaoning Cheng Da Co.,Ltd.

https://en.chengda.com.cn/

Liaoning Cheng Da Co., Ltd. is a diversified conglomerate operating across several strategic sectors, including biopharmaceuticals, financial services, energy development, and international trade. The company is a prominent player in the biopharmaceutical field through its specialized subsidiaries, focusing on the research, development, and production of human vaccines, most notably its market-leading purified Vero cell rabies vaccine. In the energy sector, it engages in the extraction and processing of oil shale. Its financial services division involves significant investments in securities firms and insurance companies. Additionally, the company maintains a robust international trade business, dealing in commodities such as textiles and chemicals. Liaoning Cheng Da focuses on integrating industrial operations with financial capital to drive growth across its various business units.

Recent filings

Filing Released Lang Actions
辽宁成大股份有限公司独立董事关于第十届董事会第七次（临时）会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on specific board meeting matters, specifically regarding the approval of commodity and foreign exchange derivatives business for the year 2022. It references compliance with company law, securities law, and stock exchange listing rules, and is dated February 11, 2022. The content is focused on governance and board-level decisions rather than financial results, audit, or shareholder voting outcomes. It is not a full annual report, audit report, or earnings release. It is also not a simple announcement or certification but a formal opinion from independent directors on board matters. This fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to the company's board or senior management activities.
2022-02-11 Chinese
辽宁成大股份有限公司关于为控股子公司融资提供担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of providing guarantees for financing to the company's controlling subsidiaries. It details the guarantee amounts, the companies involved, financial data of the subsidiaries, and the board's opinion on the guarantees. There is no indication that this is a full financial report, audit report, or earnings release. The document is a formal announcement about financing-related guarantees, which fits the category of Capital/Financing Update (CAP). The document length is under 5,000 characters and contains substantive information about financing guarantees, not just a brief notice or report publication announcement. Therefore, the most appropriate classification is CAP.
2022-02-11 Chinese
辽宁成大股份有限公司关于2022年度开展商品衍生品业务的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by the board of directors of 辽宁成大股份有限公司 regarding the company's plan to engage in commodity derivatives business for the year 2022. It details the scope, scale, risk management, accounting policies, and independent directors' opinions on the matter. The document is a formal disclosure about a new business activity and risk management related to commodity derivatives, not a financial report, earnings release, or regulatory certification. It does not contain financial statements or quarterly/yearly results. It is a regulatory announcement informing shareholders and the market about the company's operational plans and risk controls. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-02-11 Chinese
辽宁成大股份有限公司关于2022年度开展外汇衍生品业务的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by the board of directors of 辽宁成大股份有限公司 regarding the company's plan to conduct foreign exchange derivative business in 2022. It includes details about the business scope, risk management, accounting policies, and independent directors' opinions. The document is relatively short (1704 characters) and serves as a formal public announcement of a business decision rather than a detailed financial report or audit. It does not contain financial statements, earnings data, or detailed management analysis. It is not a report publication announcement since it contains substantive content about the business activity itself. The document fits best into the category of Regulatory Filings (RNS) as it is a regulatory announcement about a new business activity and risk management related to foreign exchange derivatives, which does not fall under other more specific categories.
2022-02-11 Chinese
辽宁成大股份有限公司股东集中竞价减持股份进展公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding the progress of a major shareholder's planned reduction of shares through centralized bidding. It details the shareholder's current holdings, the planned reduction amount, the progress of the reduction plan, and the impact on company control and governance. There are no financial statements, earnings data, or detailed financial analysis present. The document is a regulatory announcement about shareholding changes and reduction plans, not a full financial report or earnings release. It fits the category of Major Shareholding Notification (MRQ) as it informs about changes in significant share ownership levels and related plans.
2022-02-10 Chinese
辽宁成大股份有限公司关于股东股份质押延期购回的公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement by Liaoning Chengda Co., Ltd. regarding the extension of the repurchase period for pledged shares by a shareholder and its related parties. It details the number of shares pledged, the pledge extension dates, and the shareholder's cumulative pledged shares. The content focuses on share pledge and repurchase arrangements, which relate to changes in shareholding and capital structure but do not constitute a full financial report or earnings release. The document is relatively short (3026 characters) and is an official announcement about share pledge extension, not a report or detailed financial statement. Therefore, it fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding share pledges and capital changes.
2022-01-27 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.